Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) will announce its earnings results before the market opens on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) last announced its earnings results on Thursday, May 12th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.09. On average, analysts expect Spectrum Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Spectrum Pharmaceuticals Price Performance
Shares of NASDAQ SPPI opened at $0.88 on Thursday. The company has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.86. Spectrum Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $3.26. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.38 and a current ratio of 2.38. The company has a market capitalization of $158.48 million, a price-to-earnings ratio of -1.00 and a beta of 2.01.
Wall Street Analyst Weigh In
Institutional Investors Weigh In On Spectrum Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in SPPI. Mirabella Financial Services LLP purchased a new stake in Spectrum Pharmaceuticals in the first quarter worth approximately $27,000. Ergoteles LLC purchased a new position in shares of Spectrum Pharmaceuticals during the 1st quarter worth $386,000. Acadian Asset Management LLC boosted its stake in shares of Spectrum Pharmaceuticals by 1,355.2% during the 1st quarter. Acadian Asset Management LLC now owns 421,867 shares of the biotechnology company’s stock worth $543,000 after acquiring an additional 392,877 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Spectrum Pharmaceuticals by 5.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 432,628 shares of the biotechnology company’s stock worth $559,000 after acquiring an additional 22,726 shares during the last quarter. Finally, Panagora Asset Management Inc. boosted its stake in shares of Spectrum Pharmaceuticals by 40.4% during the 1st quarter. Panagora Asset Management Inc. now owns 849,041 shares of the biotechnology company’s stock worth $1,095,000 after acquiring an additional 244,100 shares during the last quarter. Hedge funds and other institutional investors own 58.51% of the company’s stock.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.